Cargando…
免疫检查点抑制剂治疗少见突变非小细胞肺癌疗效的研究进展
Over the past several decades, advances in driven targeted therapy has revolutionized the management of oncogene-driven non-small cell lung cancer (NSCLC). However, there are only a few targeted drugs available for patients with rare mutations, such as BRAF, HER2, MET, RET, etc. In recent years, imm...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849033/ https://www.ncbi.nlm.nih.gov/pubmed/33478186 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.41 |